NABI BIOPHARMACEUTICALS : CGEN

Profil supprimé

23 juin 2011 •01:10

tout comme IPXL : j'aime bcp le Graph ; reste à gratter...

Dernier Cours ($) 3.99
CB (mlns $) 136,020
Revenus 2010 (mlns $) 1.11
Budget R&D 2010 (mlns $) 6.24
Résultat Net 2010 (mlns $) -7.20
Cash (mlns $) 25,530
Autonomie Cash (mois) 93
Dettes totales (mlns $) 0.00
CASH/CB (%) 19%
Valo Pipeline (mlns $) 110,490
Prochains Résu financiers 27-Jul/3-Aug-11
Derniers Résu financiers 11-May-11

Evolution sur 3 Mois -19.30%
Evolution sur 6 Mois -18.40%
Evolution sur 12 Mois -0.50%
Plus haut sur 1an ($) 5.8
Plus bas sur 1an ($) 3.04
MM 50 jours ($) 4.37
MM 200 jours ($) 4.79
Volume moyen (3 mois) 55789
Volatilité (Beta) 1.78
Consensus Analystes NA
Part des instit. (% K) NA
Short Ratio (jours) 2
Short (% du K) 0.30%
Nombre d'Employés 39

> A PROPOS DE CGEN >

When a drug is a mere twinkle in a scientist's eye, Compugen is there. The Israeli drug discovery company uses its expertise in computer sciences and molecular biology to predict molecular behavior and discover potential therapies and diagnostic biomarkers. It then licenses those discoveries -- focused mainly in the areas of cancer, cardiovascular disease, and immune disorders -- to other drug firms for further development, in return for milestone payments and future royalties. Compugen has formed licensing and collaboration partnerships with numerous companies, including Biosite, Ortho-Clinical Diagnostics, and Roche